WO2002096429A1 - Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant - Google Patents

Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant Download PDF

Info

Publication number
WO2002096429A1
WO2002096429A1 PCT/RU2002/000267 RU0200267W WO02096429A1 WO 2002096429 A1 WO2002096429 A1 WO 2002096429A1 RU 0200267 W RU0200267 W RU 0200267W WO 02096429 A1 WO02096429 A1 WO 02096429A1
Authority
WO
WIPO (PCT)
Prior art keywords
per
finished product
medium
amount
psoriasis
Prior art date
Application number
PCT/RU2002/000267
Other languages
English (en)
Russian (ru)
Inventor
Vyacheslav Vitalievich Barbinov
Roman Arikovich Grashin
Aleksey Viktorovich Samtsov
Vladimir Nikolaevich Atamanchuk
Vyacheslav Anatolievich Jurieshev
Sergey Dmitrievich Tsiembalov
Sergey Ivanovich Petrov
Original Assignee
Muratov, Igor Aleksandrovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Muratov, Igor Aleksandrovich filed Critical Muratov, Igor Aleksandrovich
Publication of WO2002096429A1 publication Critical patent/WO2002096429A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Definitions

  • the invention is only for external use and may be used for external therapy.
  • the methods of treating the disease with the use of physical exposure to the affected skin are known.
  • ⁇ a ⁇ , na ⁇ ime ⁇ , izves ⁇ en s ⁇ s ⁇ b treatment dissemini ⁇ vann ⁇ g ⁇ ⁇ s ⁇ iaza, v ⁇ lyuchayuschy se ⁇ al- hydrochloric ⁇ i ⁇ des ⁇ u ⁇ tsiyu ⁇ chag ⁇ v ⁇ azhen ⁇ 4ya ⁇ zhi, s ⁇ glasn ⁇ ⁇ mu ⁇ e ⁇ ed ⁇ i ⁇ des ⁇ u ⁇ tsiey ⁇ izv ⁇ dya ⁇ ⁇ b ⁇ ab ⁇ u ⁇ i ⁇ e ⁇ m and ⁇ i ⁇ v ⁇ zdeys ⁇ - Wier che ⁇ eduyu ⁇ with gem ⁇ s ⁇ btsiey ( ⁇ , 2036667).
  • Access to this equipment is a complication of implementation, due to the need to use special equipment.
  • physiological oil at a temperature of 50-60 ° C and the target product
  • exudative disease The means of medication for the treatment of a disease are known.
  • Alkylglycerol ( ⁇ ⁇ , 1837877).
  • the raw materials are sold by the consumer and the consumables are in accordance with the quality of the raw materials used by the manufacturer, and the
  • the extraction is carried out by the processor, the extract is evaporated, and the calculation is taken by the extraction of lipids from the oxygen concentrate of 15
  • the cost of this method is the complexity of implementation.
  • the means for external therapy of a disease including active and fertile substances, are subject to
  • the equipment may optionally be equipped with ⁇ 2 - accessories,
  • piropoxane in the amount of 0.005 - 0.18 g per 1 g of finished product or sugar in the amount of 0.012 - 0.12 g per 1 g of finished product in the amount of 0.012 - 0.12 g per 1 g of finished product
  • varieties in amounts of 0.002–0.012 g per 1 g of finished product or salbutamum in amounts of 0.002–0.012 g per 1 g of finished product are examples.
  • the improved liposomal emulsion adds a fat base
  • a ready-made product in the form of an aroma is obtained.
  • Declared medium may be sold using
  • the food supplement “Lecithin” mixed with a cleaner at a ratio of 1: 1 in case of deterioration is spilled into the flask.
  • its residues (steams) are removed by blowing the flask with nitrogen.
  • a flask containing the declared active substances is introduced into the flask. Then, for a period of time, continuous stirring of the continuous flask is carried out at a temperature of 36 -
  • the treatment of the disease was carried out by the plant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention vise une nouvelle forme de médicament destinée au traitement du psoriasis de l'extérieur aux stades aigus de cette maladie. Le produit destiné au traitement du psoriasis de l'extérieur est caractérisé en ce que l'on utilise en tant que substances actives des préparations du groupe des méthylxanthines, des préparations de sélénium et quelques additifs; en tant que composés supplémentaires on utilise une base lipidique, de l'huile végétale raffinée et de l'eau. L'additif alimentaire 'Lécithine', mélangé à du cholestérol dans des proportions 1 à 1 par rapport à la phosphatidylcholine, est dissout dans le chloroforme. Après l'évaporation du chloroforme on injecte dans la fiole une solution contenant les substances actives de l'invention. On procède ensuite au mélangeage du contenu de la fiole à une température entre 36 et 40 °C, ce qui permet d'obtenir une émulsion liposomale qui, additionnée d'une base lipidique (lanoline) et d'une huile végétale (p.ex., huile d'olives), forme après le mélangeage un produit prêt se présentant comme une crème ayant la consistance voulue. Le produit de l'invention se distingue avantageusement de tous les produits connus par le succès de son utilisation aux stades aigus de la maladie, lorsque d'autres produits tels que le goudron et l'anthraline sont contre-indiqués, ainsi qu'en cas de psoriasis exsudatif et de psoriasis du cuir chevelu, lorsque les produits connus se montrent inefficaces.
PCT/RU2002/000267 2001-05-29 2002-05-23 Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant WO2002096429A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001114783 2001-05-29
RU2001114783/14A RU2196583C1 (ru) 2001-05-29 2001-05-29 Средство для наружной терапии псориаза и способ его изготовления

Publications (1)

Publication Number Publication Date
WO2002096429A1 true WO2002096429A1 (fr) 2002-12-05

Family

ID=20250213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000267 WO2002096429A1 (fr) 2001-05-29 2002-05-23 Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant

Country Status (2)

Country Link
RU (1) RU2196583C1 (fr)
WO (1) WO2002096429A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2456976C1 (ru) * 2010-12-27 2012-07-27 Роман Арикович Грашин Лекарственная композиция для лечения заболеваний кожи (варианты)
RU2724049C1 (ru) * 2019-04-11 2020-06-19 Роман Арикович Грашин Средство для наружной терапии наиболее часто встречающихся дерматозов

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
US5565462A (en) * 1991-09-02 1996-10-15 Teva Pharmaceutical Industries, Ltd. Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative
RU2125443C1 (ru) * 1993-12-30 1999-01-27 Л'Ореаль Косметическая или дерматологическая композиция для одновременного лечения поверхностных и глубоких слоев кожи и ее применение
RU2152218C1 (ru) * 1998-04-21 2000-07-10 Дальневосточный государственный медицинский университет Способ лечения псориаза
RU2163486C1 (ru) * 2000-03-28 2001-02-27 Щиголева Светлана Александровна Средство для лечения псориаза, витилиго и алопеции

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
US5565462A (en) * 1991-09-02 1996-10-15 Teva Pharmaceutical Industries, Ltd. Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative
RU2125443C1 (ru) * 1993-12-30 1999-01-27 Л'Ореаль Косметическая или дерматологическая композиция для одновременного лечения поверхностных и глубоких слоев кожи и ее применение
RU2152218C1 (ru) * 1998-04-21 2000-07-10 Дальневосточный государственный медицинский университет Способ лечения псориаза
RU2163486C1 (ru) * 2000-03-28 2001-02-27 Щиголева Светлана Александровна Средство для лечения псориаза, витилиго и алопеции

Also Published As

Publication number Publication date
RU2196583C1 (ru) 2003-01-20

Similar Documents

Publication Publication Date Title
DE69930792T2 (de) Verfahren zur Herstellung eines Propolis-Extraktes, das einenm Anionenaustauschschritt umfasst
KR100539495B1 (ko) 글리코실-엘-아스코르브산의아실화유도체
TWI550063B (zh) Antioxidant composition
JP4002654B2 (ja) 血中脂質改善剤、サイクリックａｍｐホスホジエステラーゼ阻害剤、及び肥満の予防・解消剤、並びに飲食品及び皮膚外用剤
JP4812222B2 (ja) ミネラル吸収促進剤
JP5027361B2 (ja) ヒアルロン酸産生促進剤
WO2001049822A2 (fr) Agents physiologiquement actifs contenant dithioglyols et leur application dans differentes secteurs
WO2002096429A1 (fr) Agent therapeutique pour traiter le psoriasis de l'exterieur et procede de fabrication correspondant
CN107669536A (zh) 一种桑树茶油祛痘膏及用法食品药膏日化品理疗药膏
JP4641090B2 (ja) 高血圧症予防・治療剤
JP2004137218A (ja) 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物
JP2004137287A (ja) 高血圧症予防・治療剤
JP2008088131A (ja) 抗コレステロール組成物
JPH0912466A (ja) 脂質の吸収阻害・排出促進剤および高脂肪食品
CN107550963A (zh) 一种千里光消疮液及用法食品药液日化品理疗药液含护肤
CN107456468A (zh) 一种杉皮茶油袪疤痕膏及用法食品药膏日化品理疗药膏
CN107412445A (zh) 一种柏枝茶油止血膏及用法食品药膏日化品理疗药膏
TW470749B (en) Propolis extract with improved water-solubility
JP2002080357A (ja) 高血圧症予防・改善・治療剤
RU2127068C1 (ru) Биоактивный препарат "доброй ночи"
KR20140059957A (ko) 꾸지뽕나무 열매의 추출물을 포함하는 비만 치료 및 개선용 조성물
EP0263126A1 (fr) Compositions roborantes sous forme d'emulsion stable
Taylor Herbal detox: Ease the load on your metabolism in natural ways
RU2199328C1 (ru) Состав, обладающий общеукрепляющим и тонизирующим действием
KR20230173476A (ko) 로열젤리 및 프로폴리스 원괴의 혼합물을 포함하는 항산화용 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KP LT LV MK MX NO PL RO SG SI SK TR UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: DEEMED TO BE WITHDRAWN AS FEES WERE NOT PAID WITHIN SPECIFIED TIME LIMITS

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP